IXICO plc EUR1m funding as a partner in major EU consortium (0744M)
October 10 2016 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 0744M
IXICO plc
10 October 2016
10 October 2016
IXICO plc
("IXICO" or the "Company")
IXICO to receive EUR1m funding as a partner in a major EU
public-private consortium
Potential for long-term revenue opportunities through developing
novel diagnostic and disease management technologies for
Alzheimer's Disease
IXICO, the brain health company, today announces its
participation in the Innovative Medicines Initiative focused on
Amyloid Imaging to Prevent Alzheimers Disease (AMYPAD). This
innovative collaboration between leading academic, healthcare and
pharmaceutical partners, including GE Healthcare, Piramal Imaging
and Janssen Pharmaceutica JPNV, will investigate the use of amyloid
brain scans to improve the diagnosis and management of Alzheimer's
Disease (AD).
IXICO's TrialTracker(R) and Assessa(R) technology platforms will
be deployed at the heart of this five year project to evaluate and
enhance the way that amyloid PET scans can be used to support the
development of new therapies for the treatment of patients with AD.
Amyloid PET can image the <BETA>-amyloid molecules in the
brain that are associated with AD and which accumulate in the brain
long before serious symptoms appear. Through understanding
<BETA>-amyloid, AMYPAD aims to improve the diagnosis and
management of the disease, understand the natural history in
pre-symptomatic stage and select people for treatment or trials
aimed at preventing AD.
The Company will receive EUR1 million over the life of the
project, for the use of TrialTracker(R) and Assessa(R) technology
platforms, covering the cost of the Company's participation.
Derek Hill, CEO of IXICO, said: "IXICO is proud to be
participating in this important initiative. Our involvement in the
AMYPAD project demonstrates not only our continued success in
deploying our key technology platforms across major
neurodegenerative disease indications, including our collaboration
with Biogen and clinical centres in multiple sclerosis, but also
our longstanding reputation and experience in Alzheimer's Disease.
AD has a significant impact on peoples' lives and we believe that
with the help of IXICO's expertise, AMYPAD may pave the way to
improve the prevention, diagnosis and treatment of people living
with this disease."
Dr Gill Farrar, AMYPAD Project leader and Scientific Director at
GE Healthcare Life Sciences, commented: "AMYPAD will apply amyloid
PET on an unprecedented scale to patients who are suspected to be
in the early stages of AD and generate the knowledge to fully
integrate PET <BETA>-amyloid markers into current clinical
practice in a cost-efficient way, by demonstrating its diagnostic,
prognostic and therapeutic value from a multi-stakeholder
perspective."
AMYPAD will utilise the European-wide register of 24,000
patients created by the European Prevention of Alzheimer's Dementia
Initiative (EPAD), of which IXICO is also a partner. IXICO's
TrialTracker(R) platform will collect and manage 6,000 Amyloid PET
scans acquired at clinical centres across Europe and Assessa(R)
will be used to analyse PET data, combined with other data captured
from patients, to help identify those people who could benefit from
enrolment in clinical trials aimed at preventing AD.
For further information please contact:
IXICO plc
Derek Hill, Chief Executive Officer Tel: +44 20 3763
Susan Lowther, Chief Financial 7499
Officer
Shore Capital (Nomad and Broker) Tel: +44 20 7408
Bidhi Bhoma / Edward Mansfield 4090
FTI Consulting Limited (Investor Tel: +44 20 3727
Relations) 1000
Simon Conway/Mo Noonan/Matthew
Moss
About IXICO
IXICO's innovative and proprietary digital healthcare
technologies help those involved in researching and treating
serious diseases to capture and analyse clinical data to make
rapid, informed decisions. In clinical research this includes the
phenotyping of patients, quantification of disease pathology and
measurement of patient outcomes. In clinical practice the mobile
health and digital decision support technologies aid diagnosis,
patient engagement and monitoring. IXICO is also collaborating with
partners to develop companion digital health products targeted at
improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease,
Huntington's disease, multiple sclerosis, Parkinson's disease,
behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
About AMYPAD
AMYPAD is a novel research initiative between academic and
private research partners to investigate the value of
<BETA>-amyloid using positron emission tomography (PET)
imaging as a diagnostic and therapeutic marker for Alzheimer's
dementia. AMYPAD is mainly sponsored by the European Union's
Horizon 2020 research and innovation programme and the European
pharmaceutical industry (via EFPIA) under the Innovative Medicines
Initiative.
About the EPAD Platform/Register
The EPAD platform will draw European participants, whose records
are already part of existing national/regional cohort or register
studies, into an EPAD register of approximately 24,000 people. From
this group, 6,000 people will be asked to join a pan-European EPAD
Cohort for consistent, longitudinal follow-up, and approximately
1,500 of them will eventually be invited to enter the EPAD Proof of
Concept Trial. This approach aims to ensure EPAD has access to an
at-risk population showing biomarker evidence of Alzheimer's
disease prior to the development of dementia.
About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is Europe's largest
public-private initiative aiming to speed up the development of
better and safer medicines for patients. IMI supports collaborative
research projects and builds networks of industrial and academic
experts in order to boost pharmaceutical innovation in Europe. IMI
is a joint undertaking between the European Union and the European
Federation of Pharmaceutical Industries and Associations,
EFPIA.
More information can be found at www.imi.europa.eu
Acknowledgement
The research leading to these results has received support from
the Innovative Medicines Initiative Joint Undertaking, resources of
which are composed of financial contribution from the European
Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA
companies' in kind contribution.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUGGUGUUPQGCB
(END) Dow Jones Newswires
October 10, 2016 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024